Redhall wins a target price upgrade by Frost & Sullivan
The company's share rose 1% after a 13% drop since the beginning of the month
Radhill is now up to the target price of Frost & Sullivan as part of the Tel Aviv Stock Exchange analysis project, and is expected to climb to a market value of NIS 809 million, compared with a current value of 560 NIS 4.72 per share, an upside of 46%.
Prost and Sullivan explain the increase in the target price by a number of key points, including the company's announcement that it is accelerating the trial schedule of the 104-RHB indicator for Crohn's disease in the US, with registration expected to end by November 2017, 2016. Radhill estimates that this will also save about $ 50 million in costs, and the company's announcement of positive results in the Phase II trial of BEKINDA (treatment of irritable bowel syndrome) and the continuation of Phase III study to obtain FDA approval . (To the full article)
Frost & Sullivan: "The company is advancing our assessment of its strategy and clinical development, and Redhill has added a new drug to the two drugs it currently sells in the US and continues to expand its sales platform in the US We expect these drugs to start generating significant revenues. The results of Phase 2 of BEKINDA have already been integrated into our latest report and the results of Phase 3 are expected to be published next year. "
"Redhill has announced the acceleration of Phase III trials of Crohn's disease, and we believe that the company is interested in statistically significant results with fewer patients, cost savings and faster market access, and we believe that the company may indeed have statistically significant results as it expects. We are adopting RedHeal's assessment of positive results in the MAP study. Therefore, the acceleration of the trial may bring the drug to market by 2020. Since we do not have specific information about the reduction Research and development expenses of $ 14 million, we make a more conservative estimate Reducing costs and bringing forward sales. "
RedHeal BioPharma is an Israeli company focused on the development and commercialization of candidates for late-stage clinical drugs. The company's main focus is advanced clinical and commercial development in the United States of small oral pharmaceuticals for the treatment of gastrointestinal diseases, inflammatory diseases and cancer Radhill is currently promoting two gastrointestinal products along with other clinical programs, 3) and four stage 2 for a number of indications including multiple myeloma, carcinoma, pancreatic cancer and irritable bowel syndrome.
Redhill
--------------------------------------------------------
This article originally written in Hebrew, and GOOG automatic
translated which of course is not perfect, but one gets the idea.
Published in Bizportal.co.il
